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Abstract Objective To construct a prokaryotic expression vector bearing fusion gene NT4-ADNF-9 for future stud⁃
ies on genetic therapies for sensorineural deafness. Methods Double strand ADNF-9 cDNA was synthesized using
asymmetrical primer/ templates and ligated to the 3’terminal of signal and leader peptides of neurotrophin 4 (NT4).
The fusion gene NT4-ADNF-9, was subcloned into prokaryotic expression vector pBV220, and named pBV220/
NT4-ADNF-9. DNA sequence of the fusion gene was analyzed. The fusion protein was isolated by SDS-PAGE and
its bioactivity was evaluated using primary culture of day 8 chicken embryonic DRGcells. Results The correct se⁃
quence of fusion gene NT4-ADNF-9 was successfully subcloned into the pBV220 vector. The expressed ADNF-9
protein showed its effects in promoting cell survival and neurite growth. Conclusion Prokaryotic expression vector
pBV220/NT4-ADNF-9 was constructed successfully and the expressed fusion protein demonstrated satisfactory bio⁃
activity.
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Introduction
Neurotrophic factors（NTFs）are generally utilized as
neuroprotective agents in the treatment of Alzheimer dis⁃
ease and related neurodegenerative disorders. However,
the application is limited because these protect sub⁃
stances are difficult to pass the blood brain barrier. So it
is important to find applicable micromolecular polypep⁃
tides［1, 2］. Activity-dependent neurotrophic factor-9（AD⁃
NF-9）, a type of hypso-activity neurotrophic factors
which is generated by neuroglia cells under the effect of
vasoactive intestinal peptide（VIP）, exerts neuroprotec⁃
tive effect on neuron damage of various causes［3，4］. AD⁃
NF-9 consists of 9 amino acid and exhibits significant
neuroprotective effect at10-13~10-16 mol·L-1. AD⁃
NF-9 has less than 1 ku molecular ratio（Mr）and can
pass the blood brain barrier freely ［5］. ADNF-9 has
drawn close attention from drug developers and otolaryn⁃
gologists. In this study, we first constructed fusion gene
NT4-ADNF-9 by ligating the ADNF-9 cDNA to the 3’
terminal of signal and leader peptides of neurotrophin 4
（NT4） and then subcloned the NT4-ADNF-9 fusion
gene into a prokaryotic expression vector pBV220. The
new plasmid pBV220/ NT4-ADNF-9 was then used for
secretory expression of ADNF-9 in prokaryotic cells.
We hope this technique will facilitate future studies on
gene therapy for neurosensory deafness.
Materials and Method
1 Bacterium strains, Plasmids, Enzymes, and Agents
DH5α competent cells, LB medium, plasmid
pGEM-T Easy/NT4 and vector pBV220 were obtained
from Xi’an Huaguang Bioengineering Company. DNA
polymerase, ligase and restriction enzymes were pur⁃
chased from Huamei Bioengineering Company and
Shanghai Sangon Biological Engineering Technology &
Services Co Ltd . All agents were of analytical pure (A.
P.) grade.
2 Preparation of ADNF-9 cDNA
Sense and anti-sense primers were designed based
on the ADNF-9 sequence data from the GenBank. A
protective basic group and a Nae I enzyme cleavage site
were introduced into the 5’terminal of the sense primer.
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A protective basic group, BamH I,and Xba I enzyme
cleavage sites and a terminator were introduced into the
5’terminal of the anti-sense primer. The 3’terminal of
the anti-sense primer contained 8 amino acid basic
pairs which were complementary to the 3’terminal of
the sense primer, making the sense and antisense prim⁃
ers the templates for each other. The primer/templates
were synthesized at the Shanghai Shenggong Bioengi⁃













3 Construction of carrier（Ｆigure 1）
Plasmid pGEM-T Easy/NT4-ADNF-9 and vector
pBV220 were both cleaved with EcoR I and BamH. The
fragment that contained fusion gene NT4-ADNF-9 was
subcloned into vector pBV220 to form plasmid pBV220/
NT4-ADNF-9.
4 Confirmation of enzyme cleavage and nucleotide se⁃
quencing
All sequences were assayed by the Sanger dideoxy
chain termination technique［4］ at the Shanghai Sheng⁃
gong Bioengineering Ltd Co
5 Recombinant plasmid expression detection
E.coli DH5α cells transformed with plasmid pBV220/
NT4-ADNF-9 were grown at 30℃ in 200 mL LB medi⁃
um with ampicillin（50μg/L） until OD600 reached
0.4-0.6, followed by an 8 hour incubation at 42℃. Bac⁃
terial cells were lysed and isolated proteins were separat⁃
ed by sodium dodecyl sulfate polyacrylamide gel electro⁃
phoresis（SDS-PAGE）. The SDS-PAGE gel were
stained with Coomassie brilliant blue（0.25 g）in 90 mL
methanol, 90 mL H2O and 10 mL glacial acetic acid,
and then photographed.
6 ADNF-9 protein bioactivity test
The dorsal root ganglion（DRG）from 8 day chicken
embryo was cultured for 12 hours and then incubated
with 0.1 ul ADNF-9 protein for 24 hours. The growth of
neural ganglion cells was examined under an invert mi⁃
croscope and photographed.
Results
1 Plasmid pGEM-T Easy/ NT4-ADNF-9
Electrophoresis of plasmid pGEM-T Easy/NT4-AD⁃
NF-9 from transformed DH5α cells that had been
cleaved by EcoR I yielded an expected 300 bp fragment
（235 bp of signal peptide, 27 bp of ADNF-9 cDNA, 3
bp of terminal codons, 6 bp of 5’protective basic group,
and 24 bp of 4 restriction cleavage sites）（Figure 2）, in⁃
dicating successful subcloning of the fusion gene
NT4-ADNF-9 into plasmid pGEM-T Easy,. DNA se⁃
quencing results indicated correct DNA fragment se⁃
quence. Both the NT4 and ADNF-9 genes were located
in the same open reading frame（ORF）as shown by anal⁃
ysis using the DNASIS 2.5 software（Figure 3）.
2 Plasmid pBV220/ NT4-ADNF-9
Cleavage of plasmid pBV220/NT4-ADNF-9 with
Xba I produced an expected DNA fragment（288 bp）onFig. 1 The strategy for construction of recombinant plasmid
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electrophoresis（Figure 4）, confirming successful sub⁃
cloning of the fusion gene NT4-ADNF-9 into prokary⁃
otic expression plasmid pBV220.
3 Expression of plasmid pBV220/ NT4-ADNF-9
SDS-PAGE showed that the NT4 signal peptide（9 KD）
was present in the cell precipitation but not in the super⁃
natant（Figure 5）. The ADNF-9 peptide was not detect⁃
ed due to its low molecular weight（about 1KD）. These
results were suggestive of correct split of the signal pep⁃
tide NT4 by the E.coli DH5α endopeptidase.
4 Fusion protein NT4-ADNF-9 bioactivity
After treating with fusion protein NT4-ADNF-9,
which was isolated from transformed E.coli DH5α cells,
the chicken embryo DRG showed extended survival
time with longer neurite growth（Figure 6）compared to
Fig. 2 Electrophoresis of pGEM-T Easy/NT4-ADNF-9
A: Recombinant;
B: XbaⅠ/ pGEM-T Easy/ NT4-ADNF-9;
C: EcoRⅠ+ Bam HⅠ/ pGEM-T Easy/ NT4-ADNF-9;
D: λDNA/ Hi ndⅢ Marker 100 bp DNA Marker;
E: 100 bp DNA Marker
Fig. 3 Amino acid translation of the NT4-ADNF-9 fusion gene
Fig. 4 Electrophoresis of recombinant expression vector
pBV220/ NT4-ADNF-9
A: pBV220/ NT4-ADNF-9;
B: XbaⅠ/ pBV220/ NT4-ADNF-9;
C: EcoRⅠ+ Bam HⅠ/ pBV220/ NT4-ADNF-9;
D: λDNA/ HindⅢ Marker;
E: 100bp DNA Marker
Fig. 5 SDS-PAGE analysis of NT4-ADNF-9 fusion gene ex⁃
pression in DH5α cells
A: Supernatant of expressed pBV220/NT4-ADNF-9
B: The inclusion bodies of protein of pBV220/NT4-ADNF-9
C: Supernatant control of expressed pBV220
D: Pellet control of expressed pBV220
E: Protein molecule weight marker（MW97.4KD,66.2KD,
43KD, 31KD, 20.1KD, 14.4KD）
Fig. 6 Changes of chicken ambryonic DRG after 24 hours
of incubation with ADNF-9. Note the neuronal processes
erupting around the circumferential DRG
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the control cells（Figure 7）.
Discussion
NTFs are a category of chemokines that can promote
neuronal survival, growth, differentiation and function⁃
ing. They are not only key factors for establishing func⁃
tional connection between neurons and with other cells,
but also function-regulating factors for mature neurons.
They protect neurons after injury and promote neuronal
regeneration［5-12］. Lagrèze WA et al. ［9］ noted that AD⁃
NF-9 and NAP, not only increased RGC survival in vi⁃
tro but also supported neurite growth in retinal explants.
We thus hypothesize that nerve growth factors may play
a role in the prevention and treatment of neurosensory
deafness.
ADNF-9 is a nine peptide, activity-dependent neuro⁃
trophic factor. Douglas et al first chemically purified a
high-performance protein when they researched VIP in
1996, and named it ADNF. It is a glia-derived neuro⁃
trophic factor with the secretagogue property similar to
VIP［3］. In 1998, Brenneman etc. confirmed that a 9-ami⁃
no acid core peptide（ADNF-9）had greater neurotroph⁃
ic potency than its parent protein ADNF [10]. In addi⁃
tion, deletions or augmentations to ADNF-9 resulted in
significantly reduced potency in protecting cerebral cor⁃
tex cells with neurotoxin tetrodotoxin（TTX）. ADNF-9
is neuroprotective against HIV envelope protein
（GP120）, N-methyl-D-aspartate（NMDA）, the β-amy⁃
loid peptide and TTX at a broad effective concentration
range（10-16 to 10-13 M）. On the contrary, there is no
evidence that other neurotrophic factors（e.g., NGF,
EGF, PDGF, bFGF , IGF and etc.）are neuroprotective
against TTX even at a concentration range from 1 pmol
to 1μmol［11］. It is believed that ADNF-9 can pass blood
brain barrier freely for its small molecular weight（less
than 1 kb）. In addition, it can be administrated peripher⁃
ally and its effective concentration is extremely low. It
has attracted close attention by researchers and pharma⁃
ceutical developers. Because it has a short half life（only
15 minutes） and because synthetical neuroprotective
peptides are not stable and lose more than 50 percent of
their bioactivity after 24 hours at common temperatures
or even at 4 ℃ , its application in treating neurosensory
deafness is limited.
At present, synthetic peptide technology is mainly ap⁃
plied for synthesizing short peptides. In the current
study, NT4 signal peptide and its leader sequence were
fused with ADNF-9 cDNA by T4DNA ligase, to form fu⁃
sion gene NT4-ADNF-9. Fusion genes are resistant to
degradation in cells for their large molecular weights.
Review of other studies shows that complete NT4 can be
splitted to signal peptide, leader sequence and matura⁃
tion regions by the endopeptidase in E. Coli and then
correctly processed. Therefore, eukaryotic genes such as
NT4 signal peptide and its leader sequence can be ex⁃
pressed in prokaryotic organisms and their products se⁃
creted.,ADNF-9 is a short segment of a large protein
and not associated with secretory element. Fusion of AD⁃
NF-9 with a secretory gene（NT4）, as conducted in the
current study, allows secretory expression of its products
in a prokaryotic cell. A prokaryotic expression vector
pBV220 was used in the current study and AGE and
DNA sequencing verified successful NT4-ADNF-9 sub⁃
cloning into the the vector in accordance with the study
design. The successful construction of the pBV220/
NT4-ADNF-9 vector provided an opportunity of high ef⁃
ficient expression.
Gene expression in the E. Coli has been available for
more than ten years. It can be used to produce large
quantity of proteins and is useful for protein engineering
and study of protein function. The pBV220 was chosen
in this study for its high expression performance in E.
Coli. Cultured DRG cells were used to evaluate bioactiv⁃
ity of the NT4-ADNF-9 gene, and we were able to dem⁃
onstrate that NT4-ADNF-9 was expressed and post⁃
translationally processed correctly, resulting in produc⁃
Fig. 7 Control chicken ambryonic DRG, showing no neuronal
process outgrowth.
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tion of bioactive ADNF-9 protein. This technique lays a
foundation for future study on the neuroprotective ef⁃
fects of ADNF-9. It may also signals a new way of gene
therapy for neurosensory deafness.
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